AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9134641 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin bolus during PTCA
Number of subjects: 10
Study 8194140 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised response technique
Number of subjects: 1000
Study 8194140 — intervention group
Group type: COMPARATOR
Intervention: Direct questioning
Number of subjects: 1000
Study 3130756 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin (1 gm intravenous)
Number of subjects: 100
Study 3130756 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose cefazolin (1 gm intravenous followed by two additional doses, 8 hours apart)
Number of subjects: 100
Study 3130756 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (low-risk group)
Number of subjects: 100
Study 3130756 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin
Number of subjects: 100
Study 3130756 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose cefazolin
Number of subjects: 100
Study 31166807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (n = 21)
Number of subjects: 44
Study 31166807 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (n = 23)
Number of subjects: 44
Study 31166807 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (control group)
Number of subjects: 44
Study 28236680 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback on frontal alpha asymmetry
Number of subjects: 32
Study 28236680 — intervention group
Group type: COMPARATOR
Intervention: Active control training
Number of subjects: 32
Study 26060321 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 40
Study 26060321 — intervention group
Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy (COT)
Number of subjects: 40
Study 23450020 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific cutting guides (PSCGs)
Number of subjects: 80
Study 23450020 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 80
Study 21340666 — intervention group
Group type: EXPERIMENTAL
Intervention: IRI-S (S-1 plus irinotecan)
Number of subjects: 0
Study 21340666 — intervention group
Group type: COMPARATOR
Intervention: S-1 monotherapy
Number of subjects: 0
Study 18219225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 17
Study 18219225 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline K(trans)
Number of subjects: 17
Study 16430743 — intervention group
Group type: EXPERIMENTAL
Intervention: OraDisc (2 mg amlexanox), applied four times a day for 72 hours
Number of subjects: 52
Study 16430743 — intervention group
Group type: COMPARATOR
Intervention: Vehicle patches, applied four times a day for 72 hours
Number of subjects: 52
Study 16430743 — intervention group
Group type: EXPERIMENTAL
Intervention: OraDisc (2 mg amlexanox)
Number of subjects: 52
Study 15251640 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict insulin therapy (target glucose range, 80 to 120 mg/dL)
Number of subjects: 61
Study 15251640 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy (target glucose range, 180 to 220 mg/dL)
Number of subjects: 61
Study 11421871 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 microg t.d.s., subcutaneously, starting 24 hours before ERCP)
Number of subjects: 120
Study 11421871 — intervention group
Group type: COMPARATOR
Intervention: Control (no octreotide treatment)
Number of subjects: 120
Study 9285437 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD children
Number of subjects: 49
Study 9285437 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 49
Study 7870912 — intervention group
Group type: EXPERIMENTAL
Intervention: oxiracetam 1600 mg
Number of subjects: 12
Study 7870912 — intervention group
Group type: EXPERIMENTAL
Intervention: oxiracetam 800 mg
Number of subjects: 12
Study 7870912 — intervention group
Group type: EXPERIMENTAL
Intervention: oxiracetam 2400 mg
Number of subjects: 12
Study 7870912 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 3095015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position during exercise
Number of subjects: 6
Study 3095015 — intervention group
Group type: COMPARATOR
Intervention: Supine position during exercise
Number of subjects: 6
Study 30044597 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient (ADC) value on negative biopsies
Number of subjects: 122
Study 30044597 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient (ADC) value on positive biopsies
Number of subjects: 122
Study 30044597 — intervention group
Group type: COMPARATOR
Intervention: Subjective intensity of diffusion restriction
Number of subjects: 122
Study 30044597 — intervention group
Group type: COMPARATOR
Intervention: Hyper-enhancement
Number of subjects: 122
Study 30044597 — intervention group
Group type: COMPARATOR
Intervention: Interobserver agreement
Number of subjects: 122
Study 26578119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg administered 1 hour before and 1 hour after surgery
Number of subjects: 60
Study 26578119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pregabalin)
Number of subjects: 60
Study 23557492 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% miconazole nitrate shampoo
Number of subjects: 274
Study 23557492 — intervention group
Group type: COMPARATOR
Intervention: 2% ketoconazole shampoo
Number of subjects: 274
Study 22497680 — intervention group
Group type: EXPERIMENTAL
Intervention: A priori heparin administration (50 IU/kg) immediately after sheath insertion
Number of subjects: 400
Study 22497680 — intervention group
Group type: COMPARATOR
Intervention: Provisional heparin use only if radial artery patency could not be maintained, otherwise no heparin given during the procedure, with a bolus of heparin (50 IU/kg) if needed
Number of subjects: 400
Study 20185037 — intervention group
Group type: EXPERIMENTAL
Intervention: ESCAPE discharge risk model
Number of subjects: 423
Study 20185037 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge risk factors for mortality
Number of subjects: 423
Study 20185037 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified discharge score
Number of subjects: 423
Study 20185037 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrap validation of the model
Number of subjects: 423
Study 18076272 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobically-trained (T) subjects
Number of subjects: 0
Study 18076272 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 0
Study 16119039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 180 mg
Number of subjects: 48
Study 16119039 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium 10 mg
Number of subjects: 48
Study 16119039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12052269 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein receptor inhibitors (abciximab, eptifibatide, tirofiban) used with aspirin and heparin
Number of subjects: 50000
Study 12052269 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein receptor inhibitors (abciximab, eptifibatide, tirofiban)
Number of subjects: 50000
Study 10852140 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-factor lifestyle interventions (diet, exercise, smoking cessation, alcohol intake reduction)
Number of subjects: 42
Study 10852140 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial lifestyle interventions
Number of subjects: 42
Study 10852140 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-factor and multifactorial lifestyle interventions
Number of subjects: 42
Study 8813790 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Number of subjects: 60
Study 8813790 — intervention group
Group type: COMPARATOR
Intervention: Leucocyte-depleted blood transfusion
Number of subjects: 60
Study 1424183 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 50 micrograms as selenomethionine administered once daily for 2 months
Number of subjects: 52
Study 1424183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2934747 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol
Number of subjects: 48
Study 2934747 — intervention group
Group type: COMPARATOR
Intervention: Inhaled ipratropium bromide
Number of subjects: 48
Study 2934747 — intervention group
Group type: COMPARATOR
Intervention: Combination of ipratropium and fenoterol
Number of subjects: 48
Study 31308282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 100
Study 31308282 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate
Number of subjects: 100
Study 31308282 — intervention group
Group type: COMPARATOR
Intervention: Control (sterile saline)
Number of subjects: 100
Study 29171154 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial dental midline angulation of 3.5°
Number of subjects: 196
Study 29171154 — intervention group
Group type: COMPARATOR
Intervention: Pictures with midline canted in the opposite direction of nose and chin deviations
Number of subjects: 196
Study 29171154 — intervention group
Group type: EXPERIMENTAL
Intervention: Canting in the same direction as asymmetric features
Number of subjects: 196
Study 27306219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine (700 mg) and theanine (280 mg) orally 1 week before and during S-1 chemotherapy for 5 weeks.
Number of subjects: 0
Study 27306219 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving S-1 chemotherapy without cystine and theanine.
Number of subjects: 0
Study 27306219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine and theanine group
Number of subjects: 0
Study 24852424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasally applied cellulose powder
Number of subjects: 108
Study 24852424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 22742399 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 510
Study 20198404 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial repair
Number of subjects: 42
Study 20198404 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic debridement
Number of subjects: 42
Study 18601306 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmethylphenidate ER 20 mg/day
Number of subjects: 86
Study 18601306 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study 15816453 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG plus cisapride (10 mg per os thrice per day three days before the procedure and one 10-mg dose on the morning of the procedure)
Number of subjects: 115
Study 15816453 — intervention group
Group type: COMPARATOR
Intervention: PEG plus placebo
Number of subjects: 115
Study 15816453 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG plus cisapride
Number of subjects: 115
Study 12808585 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint therapy for partners of alcohol abusers
Number of subjects: 75
Study 12808585 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of patient-treatment matching dimensions
Number of subjects: 75
Study 10566565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 658
Study 10566565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 658
Study 10566565 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 5 mg once daily
Number of subjects: 658
Study 10566565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study 8977607 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially attended night time respiratory recording (NTRR)
Number of subjects: 76
Study 8977607 — intervention group
Group type: COMPARATOR
Intervention: Full polysomnography (PSG)
Number of subjects: 76
Study 8977607 — intervention group
Group type: EXPERIMENTAL
Intervention: NTRR
Number of subjects: 76
Study 31919136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 751
Study 31919136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study 31286115 — intervention group
Group type: EXPERIMENTAL
Intervention: Equia Fil/Equia Coat
Number of subjects: 34
Study 31286115 — intervention group
Group type: COMPARATOR
Intervention: Fuji IX GP Fast/Fuji Coat LC
Number of subjects: 34
Study 29037162 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive aerobic- and resistance-training program
Number of subjects: 50
Study 29037162 — intervention group
Group type: COMPARATOR
Intervention: Gentle movement control group
Number of subjects: 50
Study 27473921 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase treatment
Number of subjects: 140
Study 27473921 — intervention group
Group type: COMPARATOR
Intervention: Needle fasciotomy
Number of subjects: 140
Study 24680230 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure with response training (n=79)
Number of subjects: 246
Study 24680230 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure without response training
Number of subjects: 246
Study 24680230 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing (n=133)
Number of subjects: 246
Study 24680230 — intervention group
Group type: EXPERIMENTAL
Intervention: Response training
Number of subjects: 246
Study 24680230 — intervention group
Group type: EXPERIMENTAL
Intervention: No training
Number of subjects: 246
Study 22980549 — intervention group
Group type: EXPERIMENTAL
Intervention: Software
Number of subjects: 1103
Study 22980549 — intervention group
Group type: EXPERIMENTAL
Intervention: Piko/Software
Number of subjects: 1103
Study 22980549 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1103
Study 22980549 — intervention group
Group type: EXPERIMENTAL
Intervention: Piko
Number of subjects: 1103
Study 18274881 — intervention group
Group type: EXPERIMENTAL
Intervention: I-QoL
Number of subjects: 174
Study 18274881 — intervention group
Group type: EXPERIMENTAL
Intervention: SSI
Number of subjects: 174
Study 18274881 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 174
Study 15787022 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation strategy (two simulation sessions: normal labor and physiological jaundice)
Number of subjects: 36
Study 15787022 — intervention group
Group type: COMPARATOR
Intervention: Usual lectures (control group)
Number of subjects: 36
Study 12622744 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted hazelnuts (140°C, 40 min)
Number of subjects: 17
Study 11143848 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with coronary artery disease
Number of subjects: 127
Study 11143848 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with very high lipoprotein (a) levels (> 40 mg/dl)
Number of subjects: 127
Study 9002327 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS (glucose 20 g/l, osmolarity 311 mmol/l)
Number of subjects: 90
Study 9002327 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-osmolarity maltodextrin-based ORS (MD 50 g/l, osmolarity 227 mmol/l)
Number of subjects: 90
Study 9002327 — intervention group
Group type: EXPERIMENTAL
Intervention: High total stool output (> 300 g/kg)
Number of subjects: 90
Study 1621021 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 10
Study 1621021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6711776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine hydrochloride bolus followed by continuous morphine infusion at 0.16 mg/hour
Number of subjects: 16
Study 6711776 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of 2.3 +/- 0.6 mg morphine hydrochloride until the end of the operation
Number of subjects: 16
Study 30611229 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression alone
Number of subjects: 0
Study 30611229 — intervention group
Group type: COMPARATOR
Intervention: Decompression with instrumental fusion
Number of subjects: 0
Study 29866397 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain radiographs
Number of subjects: 116
Study 29866397 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 116
Study 29866397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both radiographs and CT scans viewed together
Number of subjects: 116
Study 27526979 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 750 mg orally
Number of subjects: 30
Study 27526979 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 900 mg orally
Number of subjects: 30
Study 27526979 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin 600 mg intravenously (i.v.)
Number of subjects: 30
Study 27526979 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (all doses)
Number of subjects: 30
Study 25462535 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir intensification in PI-treated individuals
Number of subjects: 67
Study 25462535 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir intensification
Number of subjects: 67
Study 25462535 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intensification)
Number of subjects: 67
Study 22526948 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk flexion
Number of subjects: 0
Study 22526948 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk extension
Number of subjects: 0
Study 22526948 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk involvement (flexion or extension)
Number of subjects: 0
Study 22526948 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk flexion and extension
Number of subjects: 0
Study 20107946 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal cancer resection
Number of subjects: 0
Study 20107946 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 20003828 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg daily
Number of subjects: 63
Study 20003828 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 63
Study 15836983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold CRPS 1 patients (n=13)
Number of subjects: 47
Study 15836983 — intervention group
Group type: COMPARATOR
Intervention: Warm CRPS 1 patients (n=34)
Number of subjects: 47
Study 15836983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diagnostic subgroups
Number of subjects: 47
Study 12592250 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (100 mg) administered daily by vaginal suppository
Number of subjects: 142
Study 12592250 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily by vaginal suppository
Number of subjects: 142
Study 12592250 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 142
Study 12592250 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone group
Number of subjects: 142
Study 10680454 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam antibiotics
Number of subjects: 0
Study 10680454 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8740861 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthraxin skin test
Number of subjects: 0
Study 1684273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg once daily for seven days
Number of subjects: 151
Study 1684273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 7067924 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat action tablet (60 mg d-pseudoephedrine sulfate in the coat and 60 mg d-pseudoephedrine sulfate in the core)
Number of subjects: 0
Study 7067924 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablets (two 60 mg tablets, one at 0 hour and one at 6 hours)
Number of subjects: 0
Study 28826274 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week running intervention
Number of subjects: 42
Study 28826274 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 42
Study 27655522 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocis400® (combined nutraceutical containing 400 μg folate-6-5-methyltetrahydrofolate, 3 mg vitamin B6, 5 μg vitamin B12, 2.4 mg vitamin B2, 12.5 mg zinc and 250 mg betaine) once daily for two months
Number of subjects: 104
Study 27655522 — intervention group
Group type: COMPARATOR
Intervention: Highly dosed folic acid (5 mg/day) (control group)
Number of subjects: 104
Study 24563517 — intervention group
Group type: EXPERIMENTAL
Intervention: Toenail selenium levels
Number of subjects: 1865
Study 24563517 — intervention group
Group type: EXPERIMENTAL
Intervention: SEPP1 rs7579 genetic variant
Number of subjects: 1865
Study 24563517 — intervention group
Group type: EXPERIMENTAL
Intervention: GPX1 rs17650792 genetic variant
Number of subjects: 1865
Study 24563517 — intervention group
Group type: EXPERIMENTAL
Intervention: GPX1 rs1800668 genetic variant
Number of subjects: 1865
Study 22278284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone depression prevention intervention (2 messages/day for 9 weeks)
Number of subjects: 855
Study 22278284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone depression prevention intervention
Number of subjects: 855
Study 22278284 — intervention group
Group type: COMPARATOR
Intervention: Attention control program
Number of subjects: 855
Study 20204538 — intervention group
Group type: COMPARATOR
Intervention: Model A = traditional HIV counseling and testing
Number of subjects: 251
Study 20204538 — intervention group
Group type: EXPERIMENTAL
Intervention: Model B = nurse-initiated routine screening with traditional HIV testing and counseling
Number of subjects: 251
Study 20204538 — intervention group
Group type: EXPERIMENTAL
Intervention: Model C = nurse-initiated routine screening with rapid HIV testing and streamlined counseling
Number of subjects: 251
Study 18568182 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release dipyridamole (ER-DP) plus aspirin
Number of subjects: 0
Study 18568182 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 15963617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranio-cervical flexion action training session
Number of subjects: 23
Study 15963617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study 15963617 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash group
Number of subjects: 23